Plenty of cash for Peplin
Tuesday, 02 December, 2008
Australian-US biotech Peplin has reported a healthy cash balance of US$12.8 million, in addition to a recent private placement of US$24 million.
Releasing its financial results for the quarter ended September 30 to the ASX, Peplin said it believed the balance would be sufficient to fund Phase III trials of its topical ingenol mebutate, PEP005.
PEP005 is aimed at treating solar actinic keratoses on the head and body. Peplin recently began a Phase III trial in non-head applications.
The company said it was on track to report results of its Phase IIb trial in head applications in the first quarter of 2009.
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
